Company: INTS
Filing Date: 2025-03-28
Form Type: DRS
Source: 0001628279-25-000170
Chunk: 27

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-03-28
Form: DRS
Chunk 27
---
,122,873 shares issued and outstanding, actual, shares issued and outstanding, as adjusted |     | $                                              |       2 |     |             |
| Additional paid-in capital                                                                                                                                   |     | $                                              |  69,699 |     |             |
| Accumulated deficit                                                                                                                                          |     | $                                              | -66,783 |     |             |
| Total shareholders’ equity                                                                                                                                   |     | $                                              |   2,918 |     |             |
| Total capitalization                                                                                                                                         |     | $                                              |   2,918 |     |             |

The final public offering price will be determined through negotiation between us and the Placement Agents in the offering and may be at a discount to the current market price. Therefore, the assumed offering price used throughout this prospectus may not be indicative of the final public offering price. The as adjusted information set forth in the table above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing.

A $1.00 increase or decrease in the assumed public offering price of $ per share, the last reported sale price of our Common Stock on the Nasdaq Capital Market on , 2025, would increase or decrease our cash and cash equivalents, additional paid in capital, and total stockholders’ equity on a pro forma as adjusted basis, by approximately $ , after deducting Placement Agents’ fees and estimated offering expenses payable by us, and assuming that the number of shares of Common Stock offered by us, as set forth on the cover page of this prospectus, remains the same.

An increase or decrease of 100,000 shares of Common Stock offered by us, assuming that the assumed public offering price remains the same, would increase or decrease the gross proceeds received by us by approximately $ .

The table and discussion above are based on 15,122,873 shares of Common Stock outstanding as of December 31, 2024, and excludes the following:

• 141,996 Shares of Common Stock issued after December 31, 2024;

<div align='center'>15

Confidential Treatment Requested by Intensity Therapeutics, Inc.</div>

#### Pursuant to 17 C.F.R. Section 200.83
• 2,587,129 shares of Common Stock issuable upon the exercise of outstanding stock options with a weighted average exercise price of $6.14 per share;

• 2,041,563 shares of Common Stock issuable upon the exercise of outstanding